Schwab Charles Investment Management Inc. Has $47.92 Million Holdings in Nektar Therapeutics (NASDAQ:NKTR)

Schwab Charles Investment Management Inc. boosted its stake in Nektar Therapeutics (NASDAQ:NKTR) by 14.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 802,474 shares of the biopharmaceutical company’s stock after acquiring an additional 99,192 shares during the period. Schwab Charles Investment Management Inc. owned 0.51% of Nektar Therapeutics worth $47,924,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new stake in shares of Nektar Therapeutics during the second quarter worth $34,661,000. Rubric Capital Management LP acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $23,924,000. State Street Corp raised its holdings in shares of Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after purchasing an additional 447,023 shares during the period. Vanguard Group Inc. raised its holdings in shares of Nektar Therapeutics by 3.0% during the second quarter. Vanguard Group Inc. now owns 14,009,894 shares of the biopharmaceutical company’s stock worth $273,893,000 after purchasing an additional 401,914 shares during the period. Finally, Neuberger Berman Group LLC acquired a new stake in shares of Nektar Therapeutics during the third quarter worth $5,398,000. 96.00% of the stock is currently owned by hedge funds and other institutional investors.

In related news, CEO Howard W. Robin sold 83,333 shares of the stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the transaction, the chief executive officer now owns 272,768 shares in the company, valued at approximately $15,190,449.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christopher A. Kuebler sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the transaction, the director now owns 70,500 shares of the company’s stock, valued at approximately $4,135,530. The disclosure for this sale can be found here. Insiders sold a total of 196,666 shares of company stock valued at $12,718,923 in the last quarter. 6.10% of the stock is currently owned by insiders.

Nektar Therapeutics (NASDAQ NKTR) opened at $84.00 on Thursday. The stock has a market cap of $11,914.01, a PE ratio of -116.67 and a beta of 2.04. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 12-month low of $12.50 and a 12-month high of $99.02.

NKTR has been the subject of several recent research reports. Canaccord Genuity restated a “buy” rating and set a $80.00 price target (up previously from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Mizuho upped their price target on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 14th. Jefferies Group restated a “buy” rating and set a $35.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, November 8th. JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 price target on shares of Nektar Therapeutics in a research report on Monday, November 13th. Finally, Zacks Investment Research lowered shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and an average target price of $46.17.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://weekherald.com/2018/02/15/schwab-charles-investment-management-inc-has-47-92-million-position-in-nektar-therapeutics-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply